Publications by authors named "Sanaz Kamalinia"
Article Synopsis
- Newer antihyperglycaemic agents (AHA) like DPP4i, GLP1RA, and SGLT2i show a lower risk of hypoglycaemia compared to traditional treatments like sulfonylurea or insulin, but their risk against placebo was unclear.
- A systematic review analyzed trials over 12 weeks to evaluate the risk of both any and severe hypoglycaemia associated with AHA and metformin compared to placebo.
- Results indicated that AHA did not significantly increase hypoglycaemia risk whether used alone or with metformin, while metformin alone and early dual therapy initiation raised the risk of any hypoglycaemia.